Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies
Emilie R Elliot, Aikaterini Theodoraki, Lakshmi R Jain, Neal J Marshall, Marta Boffito, Stephanie E Baldeweg and Laura J Waters
DOI: https://doi.org/10.7861/clinmedicine.16-5-412
Clin Med October 2016 Emilie R Elliot
AChelsea and Westminster Hospital, London, UK
Roles: specialty registrar in HIV/genito-urinary medicine
Aikaterini Theodoraki
BUniversity College London Hospitals Foundation Trust, London, UK
Roles: specialty registrar in endocrinology
Lakshmi R Jain
CMortimer Market Centre, London, UK
Roles: specialty registrar in GUM/HIV
Neal J Marshall
DIan Charleson Centre for HIV Medicine, Royal Free London NHS Foundation Trust, London, UK
Roles: specialty pharmacist in HIV
Marta Boffito
EChelsea and Westminster Hospital, London, UK
Roles: HIV consultant physician
Stephanie E Baldeweg
FUniversity College London Hospitals Foundation Trust, London, UK
Roles: consultant physician in diabetes and endocrinology
Laura J Waters
GMortimer Market Centre, London, UK
Roles: HIV consultant physician
Article Figures & Data
Figures
Tables
Supplementary material
Files in this Data Supplement:
Article Tools
Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies
Emilie R Elliot, Aikaterini Theodoraki, Lakshmi R Jain, Neal J Marshall, Marta Boffito, Stephanie E Baldeweg, Laura J Waters
Clinical Medicine Oct 2016, 16 (5) 412-418; DOI: 10.7861/clinmedicine.16-5-412
Citation Manager Formats
Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies
Emilie R Elliot, Aikaterini Theodoraki, Lakshmi R Jain, Neal J Marshall, Marta Boffito, Stephanie E Baldeweg, Laura J Waters
Clinical Medicine Oct 2016, 16 (5) 412-418; DOI: 10.7861/clinmedicine.16-5-412
Jump to section
- Article
- ABSTRACT
- Introduction
- Methods
- Results
- Discussion
- Prevention of pharmacological interaction via safe prescribing in patients treated with CYP3A4 inhibitors
- Prevention of pharmacological interaction via integration and patient empowerment
- Investigation of ICS/SAI and management of high-risk co-prescription
- Treatment of patients with symptomatic SAI
- Limitations
- Conclusion
- Conflicts of interests
- Author contributions
- Supplementary material
- References
- Figures & Data
- Info & Metrics